Supplementary Methods, Tables 1-8, Figures 1-5 from Transcriptome Analysis of Triple-Negative Breast Cancer Reveals an Integrated Mrna-Lncrna Signature with Predictive and Prognostic Value

Yi-Zhou Jiang,Yi-Rong Liu,Xiao-En Xu,Xi Jin,Xin Hu,Ke-Da Yu,Zhi-Ming Shao

DOI: https://doi.org/10.1158/0008-5472.22412967

2023-01-01

Abstract:Supplementary Methods. Supplementary Table S1. Selected mRNAs and lncRNAs by comparing the expression profiles in 33 paired tumor and adjacent normal tissues of triple-negative breast cancer. Supplementary Table S2. Primers for the real-time RT-PCR analysis of mRNAs and lncRNAs included in the signature. Supplementary Table S3. Cutoff value for each RNA. Supplementary Table S4. Univariate Cox proportional hazards regression analysis of the integrated RNA signature and clinicopathological characteristics with recurrence-free survival. Supplementary Table S5. Clinicopathologic characteristics of patients with triple-negative breast cancer who received neoadjuvant chemotherapy. Supplementary Table S6. Multivariate logistic regression analysis of the integrated RNA signature and clinicopathological characteristics with pathological complete remission. Supplementary Table S7. Top ten mRNAs co-expressed with lncRNAs AK124454 and HIF1A-AS2. Supplementary Table S8. Top ten gene-ontology terms and pathways in which the co-expressed mRNAs involved. Supplementary Figure S1. Flowchart of RNA filtration. Supplementary Figure S2. Flowchart of study design, patient selection and analytical strategy. Supplementary Figure S3. Hierarchical clustering of 33 paired tumor and adjacent normal breast tissues with the 5 differentially expressed RNAs using Euclidean distance and average linkage clustering. Supplementary Figure S4. Validation of the expression of each mRNA/lncRNA incorporated in the integrated signature in the 33 paired tumor and adjacent normal tissues from the training set using quantitative real-time polymerase chain reaction (qRT-PCR). Supplementary Figure S5. Predictive values of taxane benefit using the integrated signature.